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ClopidogrelAs of now, no study or data is available to determine the period of discontinuation of
antiplatelet therapy and the timing of elective surgery in clopidogrel treated patients. The
2011 ACCF/AHA Guidelines have a Class-I recommendation for withdrawing clopidogrel for
5 days before elective coronary artery bypass grafting. However, 5 days period may not suit
all patients as platelet count varies from 150  109/L to 450  109/L. Based on our retro-
spective data analysis, we have proposed a hypothesis to determine no of days of
discontinuation of antiplatelet therapy while taking in consideration the basal count and
life-span of platelets.
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common practice in the management of vaso-occlusive
events (e.g., stroke, acute myocardial infarction, coronary ar-
tery disease, unstable angina, percutaneous coronary inter-
vention, primary and secondary cardiovascular disease
prevention).1,2 Aspirin irreversibly inactivates a key platelet
enzyme cyclooxygenase (COX-1) thus inhibiting thromboxone
(TX-A2) generation. Clopidogrel, a prodrug has no direct an-
tiplatelet activity of its own, but its activemetabolite (R130964)
binds to the platelet P2Y12 receptor and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation.3
This inhibition persists for the entire life span of the
platelet, that varies from 8 to 10 days.4 This effect can only be
reversed by formation of new platelets.5
Continuation of antiplatelet drugs is associated with
increased risk of intraoperative and postoperative bleeding
and transfusion requirements during the perioperative
period.2,6 On the other hand, stopping antiplatelet therapy for
prolonged period may put such patients at increased risk of
ischemic insult. Most tests used to demonstrate inhibitory
effects of antiplatelet drugs are expensive, too time
consuming for routine practice and are not widely available,
especially in developing countries. As of now, no study or data
is available to determine the period of discontinuation of an-
tiplatelet therapy and the timing of surgery in clopidogrel
treated patients. The 2011 ACCF/AHAGuidelines have a Class-
I recommendation for withdrawing clopidogrel for 5 days
before elective coronary artery bypass grafting.7Though there are no definite evidence-based guidelines
advocating a minimum number of platelets for major elective
surgeries, most prefer an uninhibited and functional platelet
count ofmore than 120 109/L. Assuming life spanof a platelet
8e10 days, about one tenth of platelets are newly formed and a
same number destroyed daily. Hence, following cessation of
antiplatelet therapy in a patient whose basal platelet count is
150  109/L it will take about 10 days to produce new platelet
count of 150  109/L. Therefore, a discontinuation period of 5
days may produce fresh and fully functional platelets of
75  109/L only, which is a grossly insufficient number for
effective control of bleeding. On the other hand,with the same
rate of platelet formation in a patient whose platelet count is
more than400 109/L, itmay take only fourdays or less tohave
more than 150  109/L newly formed platelets, a sufficient
number to control bleeding.
This hypothesis is based on our retrospective patient data
analysis. During the period from January 2009 to December
2013, fifty-two patients aged between 38 and 76 years, who
were on Aspirin 75 mg OD and clopidogrel 75 mg OD, had
undergone CABG following cessation of antiplatelet therapy
for five to seven days. Basal platelet count varied from
137  109/L to 355  109/L and hematocrit from 35% to 42%.
None of the patients had known coagulopathy, liver or kidney
dysfunction. Postoperatively, 44 patients had an uneventful
course however, 8 patients had blood loss ranging from 600ml
to 1100 ml in the first six hours of which five required redo
surgery for control of bleeding. Six out of those eight had
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 3 9 7e3 9 8398preoperative platelet count between 135 109/L and 155 109/
L, and two had 180  109/L and 205  109/L, respectively and
required more than ten units of platelet transfusion, peri-
operatively. Other 44 patients, who did not have significant
bleeding perioperatively, were found to have preoperative
platelet count of more than 260 109/L and required no or less
than two units of platelet transfusion.
Thus, it seems logical not to generalize the discontinuation
period of antiplatelet drugs for all patients irrespective of their
preoperative basal platelet count.
Literature search failed to find any study that shows a
direct relation of discontinuation period of antiplatelet ther-
apy in days beforemajor surgery with the platelet count of the
patient. We feel that while advising a discontinuation period
of antiplatelet therapy before major surgery, apart from other
hematological parameters ‘Basal platelet count divided by
Ten’ multiplied by number of days in order to get newly
formed fully functional platelets of more than 120  109/L, at
least. However, a prospective study is warranted to prove this
hypothesis.r e f e r e n c e s
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